Fine tuning of the Van Nuys Prognostic Index (VNPI) 2003 by integrating the genomic grade index (GGI): New tools for ductal carcinoma in situ (DCIS)

Breast Journal

Volumn 17, Issue 4, 2011, Pages 343-351

  Altintas, Sevilay ^a   Toussaint, Jerome ^b   Durbecq, Virginie ^b   Lambein, Kathleen ^c   Huizing, Manon T ^a   Larsimont, Denis ^b   Van Marck, Eric ^a   Vermorken, Jan B ^a   Tjalma, Wiebrem A ^a   Sotiriou, Christos ^b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

DCIS; genomic grading; VNPI

Indexed keywords

KI 67 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL DECISION MAKING; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENOME ANALYSIS; GENOMIC GRADE INDEX; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MULTIPLE REGRESSION; NUCLEOTIDE SEQUENCE; PATIENT IDENTIFICATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SCORING SYSTEM; VAN NUYS PROGNOSTIC INDEX;

EID: 79960392718     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2011.01091.x     Document Type: Article

References (42)

1. Wellings SR, Jensen HM,. On the origin and progression of ductal carcinoma in the human breast. J Natl Cancer 1973; 50: 1111-6. Inst.
2. Rosen PP, Braun DW, Kinne DE,. The clinical significance of pre-invasive breast carcinoma. Cancer 1980; 46: 919-25.
3. Page D, Dupont W, Rogers L, et al. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982; 49: 751-8. (Pubitemid 12165434)
4. Eusebi V, Feudale E, Foschini MP, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 1994; 11: 223-35. (Pubitemid 24308083)
5. Collins LC, Tamimi RM, Baer HJ, et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer 2005; 103: 1778-84. (Pubitemid 40563248)
6. Sanders ME, Schuyler PA, Dupont WD, et al. The natural history of low grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005; 103: 2481-4. (Pubitemid 40800525)
7. Meijnen P, Peterse JL, Bogaerts J, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853: a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006; 24: 3381-7. (Pubitemid 46638893)
8. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993-2000. (Pubitemid 29271743)
9. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003; 362: 95-102. (Pubitemid 36831018)
10. Emdin SO, Granstrand B, Ringberg A, et al. SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 2006; 45: 536-43. (Pubitemid 44167203)
11. Silverstein MJ,. The University of California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 2003; 186: 337-43. (Pubitemid 38368606)
12. Silverstein MJ,. An argument against routine use of radiotherapy for ductal carcinoma in situ. Oncology 2003; 17: 1511-33.
13. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
14. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74. (Pubitemid 32878711)
15. Van 't Veer LJ, Dai H, Van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6. (Pubitemid 34130608)
16. Van de Vijver MJ, He YD, van't Veer LJ, et al. A gene expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009. (Pubitemid 35461656)
17. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393-8. (Pubitemid 37071889)
18. Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ,. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 2006; 8: R61.
19. Allred DC, Harvey JM, Berardo M, Clark GM,. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-68. (Pubitemid 28144151)
20. Adeyinka A, Emberley E, Niu Y, et al. Analysis of gene expression in ductal carcinoma in situ of the breast. Clin Cancer Res 2002; 8: 3788-95. (Pubitemid 35424771)
21. Bryan BB, Schnitt SJ, Collins LC,. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 2006; 19: 617-21.
22. Livasy CA, Perou CM, Karaca G, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007; 38: 197-204. (Pubitemid 46096566)
23. Cornfield DB, Palazzo JP, Schwartz GF, et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer 2004; 100: 2317-27. (Pubitemid 38657878)
24. Tan PH, Bay BH, Yip G, et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 2005; 18: 374-81. (Pubitemid 40395356)
25. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26. (Pubitemid 40051905)
26. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5: 607-16. (Pubitemid 38748922)
27. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262-72. (Pubitemid 43264710)
28. Altintas S, Lambein K, Huizing MT, et al. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study. The Breast J 2009; 15: 120-32.
29. Toussaint J, Sieuwerts A, Durbecq V, et al. Molecular qRT-PCR grade index: a new tool for breast cancer (BC) patient grading improvement. Eur J Cancer 2008; 6 (Suppl): 140.
30. Sweets A,. Measuring the accuracy of diagnostic systems. Science 1988; 240: 1285-93.
31. Harrell FE, Califf R, Pryor D, Lee K, Rosati R,. Evaluating the yield of medical tests. JAMA 1982; 247: 2543-6. (Pubitemid 12155954)
32. Galea MH, Blamey RW, Elston CE, Ellis IO,. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992; 22: 207-19.
33. Gilleard O, Goodman A, Cooper M, Davies M, Dunn J,. The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. World J Surg Oncol 2008; 6:61.
34. Di Saverio S, Catena F, Santini D, et al. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat 2008; 109: 405-16. (Pubitemid 351692055)
35. Asjoe FT, Altintas S, Colpaert C, Marck EV, Vermorken JB, Tjalma WA,. The value of the Van Nuys Prognostic Index in ductal carcinoma in situ of the breast: a retrospective analysis. Breast J 2007; 13: 359-67. (Pubitemid 46985562)
36. Durbecq V, Toussaint J, Haibe-Kains B, et al., Transforming genomic grade index (GGI) into a user-friendly qRT-PCR tool which will assist clinicians and patients in optimizing treatment of early breast cancer (BC). In Proceedings of the American Society of Clinical Oncology Meeting 2007. Abstract 21058.
37. Desmedt C, Loi S, Haibe-Kains B, et al. Four genes by RT-PCR predicts distant relapse for women given adjuvant tamoxifen. Breast Cancer Res Treat 2005; 94. Abstract 3025.
38. Esserman L, Sepucha K, Ozanne E, et al. Applying the neoadjuvant paradigm to ductal carcinoma in situ. Ann Surg Oncol 2004; 11: 28S-36S.
39. Hwang ES, Esserman L,. Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results. Ann Surg Oncol 2004; 11: 37S-43S.
40. Balleine RL, Webster LR, Davis S, et al. Molecular grading of ductal carcinoma in situ of the breast. Clin Cancer Res 2008; 14: 8244-52.
41. Spyratos F, Ferrero-Pous M, Trassard M, et al. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 2002; 94: 2151-9. (Pubitemid 34411971)
42. Offersen BV, Sorensen FB, Knoop A, et al. Danish Breast Cancer Cooperative Tumor Biology Committee. The prognostic relevance of estimates of proliferative activity in early breast cancer. Histopathology 2003; 42: 573-82. (Pubitemid 38002346)